Company Description

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases.

The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases.

Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases.

The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.

KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

KALA BIO, Inc.

Country	United States
Founded	2009
IPO Date	Jul 20, 2017
Industry	Biotechnology
Sector	Healthcare
Employees	38
CEO	Avi Minkowitz

Contact Details

Address: 1167 Massachusetts Avenue Arlington, Massachusetts 02476 United States
Phone	781 996 5252
Website	kalarx.com

Stock Details

Ticker Symbol	KALA
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001479419
CUSIP Number	483119103
ISIN Number	US4831192020
Employer ID	27-0604595
SIC Code	2834

Key Executives

Name	Position
Dr. R. Kim Brazzell Ph.D.	Head of Research & Development and Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Feb 20, 2026	8-K	Current Report
Feb 17, 2026	EFFECT	Notice of Effectiveness
Feb 17, 2026	424B3	Prospectus
Feb 17, 2026	SCHEDULE 13G/A	Filing
Feb 13, 2026	D	Notice of Exempt Offering of Securities
Feb 10, 2026	S-3	Registration statement under Securities Act of 1933
Feb 6, 2026	SCHEDULE 13D	Filing
Feb 5, 2026	8-K	Current Report
Feb 2, 2026	8-K	Current Report
Jan 26, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material

View All SEC Filings